AZD2171
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Stromal Tumors
Conditions
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Trial Timeline
Sep 1, 2006 → Dec 1, 2009
NCT ID
NCT00385203About AZD2171
AZD2171 is a phase 2 stage product being developed by AstraZeneca for Gastrointestinal Stromal Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00385203. Target conditions include Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00621725 | Phase 1 | Completed |
| NCT00385203 | Phase 2 | Completed |
| NCT00243347 | Phase 1 | Completed |
| NCT00503412 | Phase 1 | Completed |
| NCT00264004 | Phase 2 | Completed |
| NCT00503477 | Phase 1 | Completed |
| NCT00502385 | Phase 1 | Completed |
| NCT00502164 | Phase 1 | Completed |
| NCT00501605 | Phase 1 | Completed |
Competing Products
20 competing products in Gastrointestinal Stromal Tumors